companies / lifebiosciences-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-25 json
| total_raised | 150,000,000150.0M | ○ |
|---|---|---|
| founded | 2016 | |
| hq | Boston, United States | |
| industry | unknown | |
| stage | series-b+ |
Life Biosciences develops partial epigenetic reprogramming therapies that revert aged cells to a younger functional state for age-related disease. It targets patients with optic neuropathies and liver disease first, expanding to broader aging conditions. Lead candidate ER-100 cleared FDA investigational use in January 2026, targeting causes rather than symptoms.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2026-04-01 | series-d+ | 80,000,00080.0M | null | ○ |
unknown
| fact | status | src |
|---|---|---|
| Series D+, $80.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |